Advertisement
Advertisement
BIIB
Biogen Inc. Common Stock
223.25
USDSponsored
+3.37
+1.53%
Oct 05, 15:23 UTC -4
Open
BIIB Earnings Reports
Positive Surprise Ratio
BIIB beat 35 of 42 last estimates.
83%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.69B
/$2.08
Implied change from Q2 26 (Revenue/ EPS)
-1.62%
/-42.22%
Implied change from Q3 25 (Revenue/ EPS)
+6.20%
/-56.67%
Biogen Inc. Common Stock earnings per share and revenue
On Jul 29, 2026, BIIB reported earnings of 3.60 USD per share (EPS) for Q2 26, beating the estimate of 3.00 USD, resulting in a 19.75% surprise. Revenue reached 2.74 billion, compared to an expected 2.51 billion, with a 9.14% difference. The market reacted with a +1.76% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 17 analysts forecast an EPS of 2.08 USD, with revenue projected to reach 2.69 billion USD, implying an decrease of -42.22% EPS, and decrease of -1.62% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
What were Biogen Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Biogen Inc. Common Stock reported EPS of $3.60, beating estimates by 19.75%, and revenue of $2.74B, 9.14% above expectations.
How did the market react to Biogen Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 1.76%, changed from $205.61 before the earnings release to $209.23 the day after.
When is Biogen Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Biogen Inc. Common Stock's next earnings report?
Based on 17
analysts, Biogen Inc. Common Stock is expected to report EPS of $2.08 and revenue of $2.69B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.